so your information would indicate that we didn't change to ASOs for the eye because we already had an interested party or someone who requested that. It seems onfe we have the results then we hope to attract some interest? Either way still a smart move to target the eye i guess as it lowers the problems we were apparently having trying to be cell specific.
It would be interesting to know if fpp are still viable for any other body parts or organs, or have they found that there is no real chance of being able to target specific cells from systemic body injection. Surely there must be some application if used with more localised or targetted application but who knows. Even if they can only target the eye now i guess it still offers economic possibilities.
PYC Price at posting:
3.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)